UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy

Tanwar, S; Trembling, PM; Hogan, BJ; Srivastava, A; Parkes, J; Harris, S; Grant, P; ... Rosenberg, WM; + view all (2017) Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. European Journal of Gastroenterology & Hepatology , 29 (3) pp. 289-296. 10.1097/MEG.0000000000000789. Green open access

[thumbnail of Accepted manuscript]
Preview
Text (Accepted manuscript)
Tanwar_Noninvasive markers of liver fibrosis_AAM.pdf

Download (164kB) | Preview
[thumbnail of Supplementary tables]
Preview
Text (Supplementary tables)
Tanwar_Noninvasive markers of liver fibrosis_Tables.pdf - Accepted Version

Download (54kB) | Preview
[thumbnail of Figure 1]
Preview
Text (Figure 1)
Tanwar_Noninvasive markers of liver fibrosis_Fig 1.pdf - Accepted Version

Download (1MB) | Preview
[thumbnail of Figure 2]
Preview
Text (Figure 2)
Tanwar_Noninvasive markers of liver fibrosis_Fig 2.pdf - Accepted Version

Download (1MB) | Preview
[thumbnail of Figure 3]
Preview
Text (Figure 3)
Tanwar_Noninvasive markers of liver fibrosis_Fig 3.pdf - Accepted Version

Download (1MB) | Preview

Abstract

AIM: The utility of noninvasive serum markers to longitudinally monitor liver fibrosis is not established. METHODS: A total of 70 patients with chronic hepatitis C who had previously failed antiviral therapy were randomized to receive pegylated interferon with or without silymarin for 24 months. Enhanced Liver Fibrosis (ELF) tests (hyularonic acid, terminal peptide of procollagen III, tissue inhibitor of matrix metaloproteinase-1) were performed on patient sera obtained before, during and at the end of the study (0, 12, 24 months) and liver histology obtained before and at the end of the study. RESULTS: At 24 months, absolute changes in Ishak fibrosis stage and ELF ranged from -4 to +4 and from -2.41 to +2.68, respectively. Absolute changes in ELF at 12 months were significantly associated with changes in both ELF and histology at 24 months. A model combining both baseline ELF and change of ELF at 12 months could predict the 24-month ELF (R=0.609, P<1×10), a decrease in ELF at 24 months [area under the curve (AUC): 0.80-0.85] and an increase in ELF at 24 months (AUC: 0.81-0.85). Furthermore, a model combining both baseline histologic stage and ELF together with the change of ELF at 12 months could predict 24-month histology (R=0.601, P<1×10, AUC: 0.88-0.92), histologic fibrosis regression (AUC: 0.81-0.84) and progression (AUC: 0.86-0.91). CONCLUSION: Our observations suggest that a change in the serum marker ELF predicts changes in liver fibrosis over a longer period. These data support the use of ELF as a surrogate marker of liver fibrosis evolution in monitoring antifibrotic treatments, thus permitting 'response-guided' therapy by the early identification of patients who will benefit from prolonged treatment.

Type: Article
Title: Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/MEG.0000000000000789
Publisher version: http://dx.doi.org/10.1097/MEG.0000000000000789
Language: English
Additional information: Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. This is a non-final version of an article published in final form in the European Journal of Gastroenterology & Hepatology [Volume 29(3), March 2017, p 289–296; doi: 10.1097/MEG.0000000000000789].
Keywords: biomarker, chronic hepatitis C, fibrosis, histology, interferon, longitudinal, silymarin
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/1533254
Downloads since deposit
202Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item